Neurocrine Biosciences on Thursday announced that two of its candidates—from separate partnerships with Xenon Pharmaceuticals and Takeda—failed their respective Phase II studies in focal onset seizures and major depressive disorder.
Tag Archive for: Neurocrine Biosciences
In a late-stage study, most Huntington’s disease patients reported that their symptoms of chorea were “much improved” or “very much improved” following treatment with Neurocrine Biosciences’ VMAT2 inhibitor Ingrezza.
Neurocrine will use these data—along with results from an open-label period—as the basis for its regulatory applications to the FDA, which the company hopes to submit in 2024. CEO Kevin Gorman said the company will also file for approval with the European Medicines Agency.
A review of the latest executive moves in the pharma industry over the past several months.
A Phase II trial studying PTC Therapeutics’ PTC518 in Huntington’s disease (HD) has been paused in the United States following a request from the FDA for additional data, the company announced Tuesday afternoon.
